Hansen K, Jorgensen S, Comert C, Schiottz-Christensen B, Bross P, Agergaard J
J Med Virol. 2025; 97(3):e70275.
PMID: 40025839
PMC: 11873671.
DOI: 10.1002/jmv.70275.
Hatayama Y, Miyakawa K, Kimura Y, Horikawa K, Hirahata K, Kimura H
Int J Mol Sci. 2025; 26(4).
PMID: 40004214
PMC: 11855120.
DOI: 10.3390/ijms26041751.
Basaca D, Juganaru I, Belei O, Nicoara D, Asproniu R, Stoicescu E
J Clin Med. 2025; 14(2).
PMID: 39860384
PMC: 11766386.
DOI: 10.3390/jcm14020378.
Herbert C, Antar A, Broach J, Wright C, Stamegna P, Luzuriaga K
Clin Infect Dis. 2024; 80(1):82-90.
PMID: 39692474
PMC: 11797388.
DOI: 10.1093/cid/ciae539.
Wu Y, Wang N, Tang Q, Shen W, Xiao W, Li J
Am J Lifestyle Med. 2024; :15598276241303692.
PMID: 39605993
PMC: 11590087.
DOI: 10.1177/15598276241303692.
Associations between physical activity, long COVID symptom intensity, and perceived health among individuals with long COVID.
Sirotiak Z, Lee D, Brellenthin A
Front Psychol. 2024; 15:1498900.
PMID: 39507087
PMC: 11538967.
DOI: 10.3389/fpsyg.2024.1498900.
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.
Evering T, Moser C, Jilg N, Ritz J, Wohl D, Li J
EClinicalMedicine. 2024; 75:102787.
PMID: 39252866
PMC: 11381616.
DOI: 10.1016/j.eclinm.2024.102787.
Antecedent and persistent symptoms in COVID-19 and other respiratory illnesses: Insights from prospectively collected data in the BRACE trial.
McDonald E, Pittet L, Barry S, Bonten M, Campbell J, Croda J
J Infect. 2024; 89(5):106267.
PMID: 39245151
PMC: 11489119.
DOI: 10.1016/j.jinf.2024.106267.
Immune system adaptation during gender-affirming testosterone treatment.
Lakshmikanth T, Consiglio C, Sardh F, Forlin R, Wang J, Tan Z
Nature. 2024; 633(8028):155-164.
PMID: 39232147
PMC: 11374716.
DOI: 10.1038/s41586-024-07789-z.
O-glycosylation of SARS-CoV-2 spike protein by host O-glycosyltransferase strengthens its trimeric structure.
Xu Z, Zhang H, Tian J, Ku X, Wei R, Hou J
Acta Biochim Biophys Sin (Shanghai). 2024; 56(8):1118-1129.
PMID: 39066577
PMC: 11399440.
DOI: 10.3724/abbs.2024127.
Relationship between acute SARS-CoV-2 viral clearance with Long COVID Symptoms: a cohort study.
Herbert C, Antar A, Broach J, Wright C, Stamegna P, Luzuriaga K
medRxiv. 2024; .
PMID: 39006428
PMC: 11245049.
DOI: 10.1101/2024.07.04.24309953.
Association of post-COVID phenotypic manifestations with new-onset psychiatric disease.
Coleman B, Casiraghi E, Callahan T, Blau H, Chan L, Laraway B
Transl Psychiatry. 2024; 14(1):246.
PMID: 38851761
PMC: 11162470.
DOI: 10.1038/s41398-024-02967-z.
The Aftermath of COVID-19: Exploring the Long-Term Effects on Organ Systems.
Golzardi M, Hromic-Jahjefendic A, Sutkovic J, Aydin O, Unal-Aydin P, Becirevic T
Biomedicines. 2024; 12(4).
PMID: 38672267
PMC: 11048001.
DOI: 10.3390/biomedicines12040913.
Single-cell immune repertoire analysis.
Irac S, Soon M, Borcherding N, Tuong Z
Nat Methods. 2024; 21(5):777-792.
PMID: 38637691
DOI: 10.1038/s41592-024-02243-4.
Cluster analysis of long COVID symptoms for deciphering a syndrome and its long-term consequence.
Niewolik J, Mikuteit M, Klawitter S, Schroder D, Stolting A, Vahldiek K
Immunol Res. 2024; 72(4):605-613.
PMID: 38627327
PMC: 11347473.
DOI: 10.1007/s12026-024-09465-w.
An effective COVID-19 vaccine hesitancy intervention focused on the relative risks of vaccination and infection.
Byerley C, Horne D, Gong M, Musgrave S, Valaas L, Rickard B
Sci Rep. 2024; 14(1):7419.
PMID: 38548828
PMC: 10978892.
DOI: 10.1038/s41598-024-57841-1.
Intra-Host Evolution Analyses in an Immunosuppressed Patient Supports SARS-CoV-2 Viral Reservoir Hypothesis.
Fournelle D, Mostefai F, Brunet-Ratnasingham E, Poujol R, Grenier J, Galvez J
Viruses. 2024; 16(3).
PMID: 38543708
PMC: 10974702.
DOI: 10.3390/v16030342.
Extracellular vesicles are a late marker of inflammation, hypercoagulability and COVID-19 severity.
Barion B, da Rocha T, Ho Y, Mazetto Fonseca B, Okazaki E, Rothschild C
Hematol Transfus Cell Ther. 2024; 46(2):176-185.
PMID: 38341321
PMC: 11150502.
DOI: 10.1016/j.htct.2023.12.003.
Characteristics of long COVID and the impact of COVID-19 vaccination on long COVID 2 years following COVID-19 infection: prospective cohort study.
Kim Y, Bae S, Chang H, Kim S
Sci Rep. 2024; 14(1):854.
PMID: 38191556
PMC: 10774352.
DOI: 10.1038/s41598-023-50024-4.
Blood-derived product therapies for SARS-CoV-2 infection and long COVID.
Wu J, Yang H, Yu D, Yang X
MedComm (2020). 2023; 4(6):e426.
PMID: 38020714
PMC: 10651828.
DOI: 10.1002/mco2.426.
